leadf
logo-loader
viewXPhyto Therapeutics Corp.

XPhyto Therapeutics brings in C$2M from placing for European imports business

The group said it plans to expand its EU lab processing and storage capacity

XPhyto Therapeutics Corp. -
As reported last week, the company struck a three-year supply and distribution deal with Colombian cultivator PharmaCielo Ltd, to serve XPhyto's German medical cannabis business

XPhyto Therapeutics Corp (CSE:XPHY) (OTCMKTS:XPHYF) has raised C$2 million gross from a fully subscribed private placing to fund its European imports business. 

In a statement on Monday, the group said it plans to expand its EU lab processing and storage capacity. The funds will also be used for regulatory compliance, inventory purchase and product development, manufacturing, and distribution, as well as for working capital.

As reported last week, the company struck a three-year supply and distribution deal with Colombian cultivator PharmaCielo Ltd, to serve XPhyto's German medical cannabis business.

READ: XPhyto Therapeutics strikes three-year cannabis supply deal with PharmaCielo for its German business

The Colombian group became its preferred supplier for its European import and distribution business and to supply premium oils and isolates for its medical cannabis products.

XPhyto sold 2,000 convertible debenture units for C$2 million gross. Each debenture unit consists of C$1,000 principal amount of 8% unsecured convertible debentures and 1,000 share purchase warrants.

The debentures bear interest at 8% a year, calculated and payable semi-annually and mature two years following the date of issue.

They are also convertible - at the option of the holder - into XPhyto shares at any time prior to the maturity date at a conversion price C$1 each.

Each warrant is exercisable to acquire one company share at an exercise price of C$1.50 per warrant share until January 31, 2022, the firm added.

XPhyto also noted today that it has issued 500,000 warrants to PharmaCielo Ltd for the above-mentioned strategic partnership and supply agreement.

Each consideration warrant is exercisable to acquire one share at an exercise price of C$2 for two years following the date of issuance.

Shares ticked up over 10% in Toronto to C$1.75 each.

---Updates for share price---

Contact the author at giles@proactiveinvestors.com

Quick facts: XPhyto Therapeutics Corp.

Price: 2.91 CAD

CSE:XPHY
Market: CSE
Market Cap: $168.81 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of XPhyto Therapeutics Corp. named herein, including the promotion by the Company of XPhyto Therapeutics Corp. in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

XPhyto Therapeutics provides update on their oral film drug delivery...

XPhyto Therapeutics (CSE: XPHY-OTC: XPHYF) CEO Hugh Rogers joined Steve Darling from Proactive to provide a look at their German subsidiary, Vektor Pharma who is currently advancing two sublingual ODF development programs for the delivery of the active pharmaceutical ingredients. Rogers...

16 hours, 1 minute ago

2 min read